过量服用通道阻断剂的血液吸收疗法:一个案例报告
Shahed Omar1, Pano Parris1, Chloe Rose Gurke1
1Department of Critical Care, School of Clinical Medicine/University of Witwatersrand/Chris Hani Baragwanath, Johannesburg, South Africa.
The Journal of emergency medicine
|March 9, 2024
概括
树脂血液输液有效地消除了阿姆洛迪平在通道阻塞剂过量服用的患者,解决了耐火性休克. 这一案例突出显示了血液输血作为一种潜在的治疗方法,用于当标准疗法失败时严重的过量服用.
科学领域:
- 毒理学 毒理学 毒理学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 临界护理医学 临界护理医学
背景情况:
- 过量服用通道阻断剂 (CCB) 由于其药理动力学特性而构成重大挑战,通常使标准的体外去除方法无效.
- 虽然ex vivo模型表明烯珠吸附可以消除CCB,但对CCB过量使用现代树脂血吸附/血 perfusion 的临床数据很少.
研究的目的:
- 描述现代树脂血吸血的临床应用和有效性,用于严重的通道阻断剂过量.
- 评估氨酸树脂血 perfusion 的潜力,以管理二次安洛迪平中毒后的耐火冲击.
主要方法:
- 一个案例报告,一名年轻的成年男性服用了阿姆洛迪平和瑞斯佩里过量,出现了耐火性休克.
- 血液动力学支持包括液体,,上腺素和高胰岛素-高血糖治疗,成功程度有限.
- 在18小时的间隔内,使用一种基于烯的过器 (Jafron HA230) 进行了两次树脂输血.
主要成果:
- 输血导致成功断了包括血管压缩剂在内的所有支持措施.
- 乳酸盐水平正常化,患者在稳定的状态下被送回家.
- 在过后的治疗过程中,高度的阿姆洛迪平因表明药物显著被清除,与临床改善相关.
结论:
- 树脂输血可能是严重通道阻断剂过量治疗的可行和有效的选择,特别是当标准疗法失败时.
- 这一案例表明,在安洛迪平中毒中,血液输血和休克解消之间存在时间关联.
- 需要进一步的研究,以确定在CCB过量管理中输血的最终作用和最佳方案.
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
517
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
517
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
512
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166


